Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 262.67M P/E - EPS this Y -4.00% Ern Qtrly Grth -
Income -60.39M Forward P/E -3.37 EPS next Y 3.20% 50D Avg Chg -4.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -14.00%
Dividend N/A Price/Book 1.64 EPS next 5Y - 52W High Chg -53.00%
Recommedations 1.90 Quick Ratio 9.58 Shares Outstanding 30.87M 52W Low Chg 49.00%
Insider Own 17.56% ROA -26.25% Shares Float 8.95M Beta -
Inst Own 69.78% ROE -41.41% Shares Shorted/Prior 1.03M/484.04K Price 11.98
Gross Margin - Profit Margin - Avg. Volume 26,562 Target Price 22.13
Oper. Margin - Earnings Date - Volume 6,367 Change -3.85%
About Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Acrivon Therapeutics, Inc. News
04/24/24 Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
04/16/24 Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
04/10/24 Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
04/09/24 Acrivon Therapeutics Announces $130 Million Private Placement Financing
03/30/24 Acrivon Therapeutics Inc (ACRV) Reports Increased Annual Loss: A Detailed Look Against Analyst ...
03/29/24 Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
03/28/24 Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
03/05/24 Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
03/04/24 Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
02/27/24 Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
02/08/24 Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
02/06/24 Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
01/12/24 Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/04/24 Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
01/03/24 Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer
11/28/23 Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
11/21/23 Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
11/21/23 Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/09/23 Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
10/16/23 Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
ACRV Chatroom

User Image intratio Posted - 04/30/24

https://www.intratio.com/stock-forecast/ACRV Our automated equity analyst deduces that this stock s value will lose ground in the coming days and will continue to have a very poor trend over the next months $ACRV

User Image Jtree123 Posted - 04/30/24

$ACRV super bullish

User Image intratio Posted - 04/29/24

https://www.intratio.com/stock-forecast/ACRV Our machine learning model has detected the market value of this company has a bad setup for the short run and will continue to trend quite negatively in the next months $ACRV

User Image THEINVESTMENTSWAMI Posted - 04/29/24

$ACRV 👁️ACRV👁️- STILL WATCHING👁️👁️👁️🧠👳‍♂️🧠

User Image PZFLY Posted - 04/29/24

$ACRV This stock needed a downgrade in order to move higher. Crazy logic out there sometimes.

User Image G101SPM Posted - 04/29/24

$ACRV $8.18 bid. DAC $9.72. EXIT $15.00. RETAIN POSITION. NOTICE: DOWNGRADE: Acrivon Therapeutics (ACRV) downgraded by Ladenburg Thalmann from Buy to Neutral.

User Image intratio Posted - 04/26/24

$ACRV https://www.intratio.com/stock-forecast/ACRV Acrivon Therapeutics, Inc. The mathematical model is predicting that this stock s price action will shortly go down and has really poor long-term fundamentals

User Image PZFLY Posted - 04/26/24

$ACRV So many upgrades and pt's from $17 to $30 and this can't even hold $9. Speaks volumes how useless and unfollowed the analysts have become.

User Image Rumponstiffskin Posted - 04/26/24

$ACRV Next week should be interesting.....

User Image Rumponstiffskin Posted - 04/26/24

If all these analyst like $ACRV and it has a $25 price target I wonder how long it will be at $8 . $BDRX $SBFM $BOF

User Image crockpot7 Posted - 04/25/24

$ACRV Upgrades and down 12% MM s at it again...

User Image PZFLY Posted - 04/25/24

$ACRV This stock gets 3 upgrades between $17 and $30 today and it trades 9% down instead to $8.70 is. Of course, this is a reflection on the uselessness of the analysts these days as well as of the state of the market.

User Image Janes15 Posted - 04/25/24

$ACRV Oh well, back to three bucks

User Image 4ENTRADES Posted - 04/25/24

$ACRV dang I bought it at $10 lol

User Image Dragan7 Posted - 04/25/24

$ACRV "Analyst Ratingsinfo icon 8 Analysts Consensus is StrongBuy 8 ratings | Overall: Strong BuylinkCaret icon Buy 100% Hold 0% Sell 0% Based on 8 analyst ratings for ACRV in the last 3 months, the overall rating is Strong Buy" Price target: Low: 14 Average: 21.71 High: 30

User Image Herrfranz Posted - 04/25/24

$ACRV small free float, buy and hold!

User Image tradethehalt Posted - 04/25/24

$ACRV trade halt (LUDP) was alerted to our Members at 9:47am EDT. Halt price: $9.10 Vol: 131.39K.

User Image Dragan7 Posted - 04/25/24

$ACRV MM and shorts manipulation. Might finish in green.

User Image HaltTradeAlert Posted - 04/25/24

$ACRV Halt Time: 09:47:19 Issue Symbol: ACRV Reason Code: LUDP Last Price: $9.1 Market Cap: $290397392 Volume: 131685.0 Relative Volume: 0.4 Shares Float: 31911800 Our members get this alert real time and sent to their phone just like a text. Members also get free real time news catalyst alerts! Go to our website and join our community for free! www.HaltTradeAlert.com

User Image tradethehalt Posted - 04/25/24

$ACRV trade halt (LUDP) was alerted to our Members at 9:34am EDT. Halt price: $8.35 Vol: 86.02K.

User Image Herrfranz Posted - 04/25/24

$ACRV added

User Image HaltTradeAlert Posted - 04/25/24

$ACRV Halt Time: 09:34:40 Issue Symbol: ACRV Reason Code: LUDP Last Price: $8.35 Market Cap: $266463542 Volume: 85173.0 Relative Volume: 0.26 Shares Float: 31911800 Our members get this alert real time and sent to their phone just like a text. Members also get free real time news catalyst alerts! Go to our website and join our community for free! www.HaltTradeAlert.com

User Image ChasingTrades Posted - 04/25/24

$HKIT 👀🤭👍 $ISUN $ONFO $CYCC $ACRV

User Image Bioze Posted - 04/24/24

$ACRV potentially one of the best risk/reward small cap oncology bios right now in the market. If future data is anywhere close to what we saw today watch out above. Best of luck to Blume-Jensen and the team. Remarkable results today!

User Image Capes Posted - 04/24/24

$ISUN $HKIT $ONFO $ACRV $CYCC

User Image tradingtwenty Posted - 04/24/24

$ACRV has trended 19 times in the past 24 hours (based on 5 minute intervals). Latest press release on Apr 24, 2024 04:01 PM: Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate.. Link: https://tradingtwenty.com/news/441991/acrivon-therapeutics-reports-initial-positive-clinical-data-for-acr-368-and-pipeline-program-progress-today-at-corporate-rd-event

User Image tradingtwenty Posted - 04/24/24

Top 5 after-hours stocks that have trended in the past 24 hours: $CDTX 40.68% 🔥 $AIRE 37.93% $ACRV 13.47% $PI 11.10% $CLS 6.73% Link: https://tradingtwenty.com/dashboard/trending/past

User Image moonshot_hunter Posted - 04/24/24

$ACRV seems like upside already priced in

User Image Dragan7 Posted - 04/24/24

$ACRV They just got 130 M pp. Enough money till end of 2025. IND in Q3 2024. Data very positive. Big pharma is watching? "A 50% confirmed overall response rate observed with ACR-368 in OncoSignature-positive gynecological (ovarian and endometrial) cancers" "ACR-2316, a potential first-in-class dual WEE1/PKMYT1 inhibitor, IND timeline accelerated with filing now expected in Q3 2024"

User Image RonIsWrong Posted - 04/24/24

$ACRV • Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) are being presented • A 50% confirmed overall response rate observed with ACR-368 in OncoSignature-positive gynecological (ovarian and endometrial) cancers • Initial clinical validation of AP3 patient selection platform, demonstrated ability to prospectively predict ACR-368 RECIST responders (p-value = 0.0038) • ACR-2316, a potential first-in-class dual WEE1/PKMYT1 inhibitor, IND timeline accelerated with filing now expected in Q3 2024

Analyst Ratings
Ladenburg Thalmann Neutral Apr 29, 24
BMO Capital Outperform Apr 26, 24
JMP Securities Market Outperform Apr 25, 24
Piper Sandler Overweight Apr 25, 24
HC Wainwright & Co. Buy Apr 25, 24
Ladenburg Thalmann Buy Apr 5, 24
BMO Capital Outperform Apr 1, 24
JMP Securities Market Outperform Apr 1, 24
HC Wainwright & Co. Buy Mar 28, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Chione Ltd 10% Owner 10% Owner Jun 12 Sell 12.26 5,893 72,248 3,850,704 06/14/23
Blume-Jensen Peter President and CEO President and CEO May 31 Option 3.88 33,605 130,387 2,403,702 06/01/23